Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study's meta-analysis found that COVID-19 vaccines are effective and safe for children, with inactivated vaccines showing the highest effectiveness and causing less injection site pain compared to attenuated vaccines.

This review discusses immunomodulatory formulations to address post-COVID conditions and reports no new clinical findings.

In this original study, researchers documented 121 COVID-19 cases with a wide range of mucocutaneous manifestations, some linked to internal organ damage and others to new vaccine-associated dermatoses, emphasizing the importance of rapid diagnosis to prevent potentially life-threatening systemic events.

This case study reports that intralesional cidofovir was successfully used for treatment without systemic toxicity, suggesting it might be an option worth considering for SCC.

This conceptual paper proposes evaluating the Ayurvedic formulation Moorvadi choornam for alleviating side effects of chemotherapy, including symptoms consistent with Garavisha lakshanas, but reports no clinical outcomes.

This review examines the implications of COVID-19 vaccination for dermatological patients with psoriasis on immunosuppressive treatment and reports no new clinical results.

This review highlights cepharanthine as a promising candidate for COVID-19 treatment due to its antiviral activity against SARS-CoV-2 and favorable pharmacokinetic and safety profile, but reports no new clinical results.

This study suggests that intralesional cidofovir might be a treatment option for SCC, as it showed a successful outcome without systemic toxicity in the reported case.

A three-year-old girl survived a rare serious infection caused by BCG vaccination, which improved after treatment with a leprosy drug.

This study found that COVID-19 vaccines were generally well-tolerated among Bangladeshi medical students, with most side effects being mild and decreasing in frequency after subsequent doses.

The authors report that a 62-year-old woman with invasive conjunctival squamous cell carcinoma experienced complete remission two years after combining cemiplimab, retinoic acid, and IFNα-2b treatments, highlighting potential utility despite limited availability of IFNα-2b.

This article reviews the impact of Covid-19 vaccinations on disease severity and mortality, noting challenges with new virus mutations and the importance of vaccine compatibility for future efficacy, but reports no new clinical results.

This study found that COVID-19 vaccination initially lowered vitamin D levels in serum and hair but increased serum levels after the second dose, except for the Pfizer group. Hair vitamin D showed a nonsignificant increase, and hair loss was most common with the AstraZeneca vaccine.

This study reports that the Pfizer-BioNTech COVID-19 vaccine showed 52% protection against COVID-19 after the first dose and 95% after the second in phase 3 trials.

In this study, hydroxychloroquine, nitazoxanide, and ivermectin demonstrated similar efficacy for overall clinical outcomes in COVID-19 when administered early with azithromycin, vitamins, and supplements, with nitazoxanide showing the strongest antiviral activity and safety profile among the three.

This review discusses the diverse range of skin manifestations in children with COVID-19 and highlights the complexity of clinical assessment due to varied presentations; it reports no new clinical findings.

This case study reports that adding adalimumab to a 12-year-old VKH patient's treatment allowed for ocular inflammation remission, vision improvement, and corticosteroid tapering, suggesting escalation of immunosuppression may be critical in pediatric VKH cases.

This study found that treatment with the synbiotic SIM01 significantly alleviated multiple symptoms of post-acute COVID-19 syndrome compared to placebo, suggesting potential management benefits through gut microbiome modulation.

This study reported that a newly formulated Curcumin-loaded proniosome, named F5, exhibited enhanced antiviral efficacy, stability, and safety when compared to Curcumin alone, and improved the therapeutic performance of Acyclovir by reducing its effective dose against Herpes simplex virus.

This case study reports a successful use of co-trimoxazole in treating a 13-year-old girl with symptoms suggestive of autoimmune disorders and relapsing polychondritis.

This study highlights that the skin can serve as a marker for systemic health during COVID-19 by showing symptoms like rashes and pigmentary changes, while also emphasizing dermatologists' key role in diagnosing COVID-induced and vaccine-related skin issues to enhance patient care and address vaccine hesitancy.

This paper discusses a case where intralesional cidofovir successfully treated squamous cell carcinoma without systemic toxicity, but surgical excision remains the standard for curative treatment and margin evaluation.

This study examined 1,992 patients at a hospital in India for signs of B12 deficiency and found common symptoms included hair loss, poor memory, and weakness. The study also reported that adding vitamin B12 powder to prepared food could improve blood levels of the vitamin.

This industry update reports on various advancements in therapeutic delivery during July 2018, highlighting active mergers, collaborations, and potential developments across fields like gene therapy, immuno-oncology, and rare diseases treatment; however, no new clinical results are presented.

This study reported that an injectable hydrogel microparticle vaccine platform enhanced antibody responses and protection against influenza in mice, outperforming the traditional adjuvant aluminum hydroxide.

This review discusses fixed drug eruption (FDE) potentially linked to finasteride and emphasizes dermatologists' need to recognize its possible occurrence due to the drug's widespread use, but reports no new clinical results.

This review summarizes the various skin manifestations linked to COVID-19 infection, vaccination, and personal protective equipment, highlighting their clinical importance and discussing psychological stress and social isolation as additional dermatologic factors.

This review examines cepharanthine's antiviral potential against COVID-19 and finds no clinical results yet; it highlights cepharanthine as a potent inhibitor of coronavirus in preclinical models.

This study confirmed known adverse events and identified new ones related to ixekizumab, offering preliminary safety insights for its clinical use, but noted limitations such as potential underreporting and confounding factors in the spontaneous adverse event reporting systems.